Filing Flows

Filing Flows › 8-K events › Fractyl Health

Fractyl Health: departure or appointment of directors and officers

Form 8-K filed Oct 22, 2026 · items 5.02, 8.01

CEO changesFractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance

What the filing says

In connection with the workforce reduction, on October 21, 2026, Jay Caplan announced his retirement. effective October 30, 2026 (the “ Separation Date ”), from his executive roles as the Company’s President and Chief Product Officer. Caplan will be entitled to severance benefits as set forth in his employment agreemen

Read the filing on SEC EDGAR →

What usually followsAcross 39,174 8-Ks reporting Item 5.02 (directors and officers: departures, appointments, pay) in our universe, the stock's median move the next session was −0.1% (typical size ±1.4%, up 48% of the time); over the following 21 sessions, +0.7%. Item 8.01: +0.1% next session across 44,881. Every item ranked →

What this kind of filing means

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

Fractyl Health at a glance

Latest quarterQ4 2024
Revenue$3K
Revenue Y/Y-57%
Operating marginn/m
IndustrySurgical & Medical Instruments & Apparatus

Fractyl Health, Q4 2024: revenue $3K (-57% year over year). The chart follows the revenue to costs, profit and cash.

Fractyl Health: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent ceo changes

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.